Letter to the Editor

Enhanced Ocular Isotretinoin Toxicity in Mitochondrial Disorder

Authors: Josef Finsterer, MD, PhD

Abstract

To the Editor:


Isotretinoin is usually administered to patients with recalcitrant nodular acne who do not adequately respond to standard topical or systemic antibiotics,1 in subfoveal occult choroidal neovascularization,2 or for chemoprevention settings.3 To the best of our knowledge, although adverse reactions of isotretinoin affect most of the organs, including the eyes,1 ocular toxicity from isotretinoin at 20 mg/d immediately after initiation of therapy in a patient with a mitochondrial disorder (MID) has not been reported.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Austria-Codex. Fachinfomration. Wien, Österreichischer Apotheker Verlag, 2006.
 
2. Lim JI, Walonker AF, Levin L, et al. One-year results of a pilot study using oral 13-cis retinoic acid as a treatment for subfoveal predominantly occult choroidal neovascularization in patients with age-related macular degeneration. Retina 2006;26:314–321.
 
3. Hanson N, Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001;20:166–183.
 
4. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007;67:75–93.
 
5. Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 2004;24:214–216.
 
6. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001;132:299–305.
 
7. Heuberger A, Buchi ER. Irreversible cataract as a possible side effect of isoretinoin. Klin Monatsbl Augenheilkd 1994;204:465–467.
 
8. Rigobello MP, Scutari G, Friso A, et al. Mitochondrial permeability transition and release of cytochrome c induced by retinoic acids. Biochem Pharmacol 1999;58:665–670.